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Cytosine base modifications in mammals underwent a recent expansion with the
addition of several naturally occurring further modifications of methylcytosine in the
last years. This expansion was accompanied by the identification of the respective
enzymes and proteins reading and translating the different modifications into chromatin
higher order organization as well as genome activity and stability, leading to the
hypothesis of a cytosine code. Here, we summarize the current state-of-the-art on DNA
modifications, the enzyme families setting the cytosine modifications and the protein
families reading and translating the different modifications with emphasis on the mouse
protein homologs. Throughout this review, we focus on functional and mechanistic
studies performed on mammalian cells, corresponding mouse models and associated
human diseases.
Keywords: cytosine modifications, Dnmt, epigenetics, hydroxymethylcytosine, MBD, methylcytosine, mouse
models, Tet
DNA MODIFICATIONS AND MODIFIERS
Cytosine Modifiers: Dnmts
In mammals, the modified cytosine was initially described by Hotchkiss (1948) and was further
extensively studied since the 1970s (Razin and Cedar, 1977). Recently, evidence for methylation of
adenine has been also reported in mammals (Koziol et al., 2016). Here, we will focus on cytosine
modifications in mammals.
DNA cytosine methylation is catalyzed by DNA methyltransferases (Dnmts) that transfer a
methyl group from S-adenosyl methionine to the fifth carbon of a cytosine residue to form 5-
methylcytosine (5mC). The majority of 5mC bases are present in CpG dinucleotides, however,
non-CpG methylation was also observed especially in mouse embryonic stem cells (mESCs) and
brain tissue (Guo et al., 2014). DNA methylation plays a major role in gene expression, cellular
differentiation, genomic imprinting, X-inactivation, inactivation of transposable elements, and
embryogenesis.
Cytosine methylation patterns are mainly established by de novo methyltransferases Dnmt3a,
Dnmt3b and their regulatory unit Dnmt3l during early embryonic and germ cell development.
Once the patterns are established, they are maintained throughout cell generations by Dnmt1
(Bestor et al., 1988; Li et al., 1992). Unlike Dnmt1 and Dnmt3a/3b, Dnmt2 is a RNA
methyltransferase rather than a DNA methyltransferase (Okano et al., 1998; Yoder and Bestor,
1998; Goll et al., 2006). A summary of the mouse Dnmt protein family and their domains
Frontiers in Genetics | www.frontiersin.org 1 June 2016 | Volume 7 | Article 115
fgene-07-00115 June 18, 2016 Time: 16:32 # 2
Ludwig et al. DNA Modifications, Readers and Modifiers
is shown in Figure 1 and a summary of the respective knockout
mice phenotypes is shown in Table 1.
De novo DNA Methylation
Overexpression of Dnmt3a and Dnmt3b is capable of methylating
both native and synthetic DNA with no preference for
hemimethylated DNA (Okano et al., 1999). The domain structure
for de novo methyltransferases Dnmt3a and Dnmt3b is similar,
including a DNA binding domain PWWP domain (Qiu et al.,
2002) and a C-terminal catalytic domain (Okano et al., 1999;
Figure 1). However, several studies showed that the distribution
and expression of Dnmt3a and Dnmt3b varies among cell
types.
Dnmt3a is expressed relatively ubiquitously and two isoforms
of Dnmt3a have been identified. One binds to euchromatic and
the other to heterochromatic regions (Okano et al., 1998; Chen
et al., 2002). Dnmt3a knockout mice developed to term and
appeared to be normal at birth but most of the homozygous
mutant mice became runted and died at about 4 weeks of age
(Table 1).
Dnmt3b is highly expressed in embryonic implantation stages,
as well as in stem cells and progenitor cells and is the major
methyltransferase in early embryogenesis (Watanabe et al., 2002,
2004). Several isoforms were identified and among all isoforms
only Dnmt3b1 and Dnmt3b2 possess DNA methyltransferase
activity (Aoki et al., 2001). No viable Dnmt3b knockout mice
were recovered at birth, further highlighting its functions in early
embryogenesis (Table 1). The major substrates of Dnmt3a/3b are
CpGs, but non-CpG methylation activity of Dnmt3a/3b was also
detected (Aoki et al., 2001).
FIGURE 1 | Schematic representation of the Dnmt protein family. Shown are domain structures of mouse Dnmt proteins and the initial references. Numbers
represent amino acid positions. DMAP, Dnmt1-associated protein binding domain; PBD, proliferating cell nuclear antigen (PCNA)-binding domain; TS, targeting
sequence; CXXC, CXXC zinc finger domain; PBHD, polybromo-1 protein homologous domain; MTase, methyltransferase; PWWP,
proline-tryptophan-tryptophan-proline motif; Cys, cysteine-rich domain.
TABLE 1 | Phenotypes of initial Dnmt knockout mouse models.
Genotype Phenotype Reference
Dnmt1 null Homozygous knockout Dnmt1 were stunted, delayed in development, and did not survive past midgestation Li et al., 1992
Dnmt3a null Knockout mice developed to term and appeared to be normal at birth but most of homozygous mutant mice became
runted and died at about 4 weeks of age
Okano et al., 1999
Dnmt3b null No viable Dnmt3b knockout mice were recovered at birth Okano et al., 1999
Dnmt2 null Mice homozygous for this Trdmt1 (formerly Dnmt2) knock-out have abnormal RNA methylation while genomic DNA
methylation patterns are not detectably altered
Goll et al., 2006
Dnmt3l null Disruption of Dnmt3l caused azoospermia in homozygous males and heterozygous progeny of homozygous female
died before midgestation
Bourc’his et al., 2001
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Although Dnmt3l does not possess DNA methylation activity
(Bourc’his et al., 2001), it strongly interacts with Dnmt3a/3b and
enhances their methylation activity (Aapola et al., 2000; Suetake
et al., 2004; Hu et al., 2008). However, high expression levels of
Dnmt3l are found only in germ cells and early stage embryos but
not in somatic cells (Watanabe et al., 2004) indicating that the
methylation activity enhancement is cell type and developmental
stage dependent. Disruption of Dnmt3l caused azoospermia in
homozygous males and heterozygous progeny of homozygous
female died before midgestation (Table 1).
Maintenance DNA Methylation
Dnmt1 has a preference for hemi-methylated DNA substrates
(Song et al., 2011) and is the enzyme responsible for the
maintenance of DNA methylation after DNA replication
(Leonhardt et al., 1992). Homozygous knockout Dnmt1 mice
were runted, delayed in development and did not survive past
midgestation (Table 1). The major isoform of Dnmt1 in mice
contains 1620 amino acids and includes an N-terminal regulatory
domain and a C-terminal catalytic domain (Tucker et al., 1996;
Yoder et al., 1996). However, one isoform lacking the most
N-terminal 118 amino acids was shown to accumulate in mouse
oocytes (Mertineit et al., 1998).
The Dnmt1-associated protein (DMAP) binding domain is
located at the beginning of the N-terminus of Dnmt1 and
it recruits DMAP1 to further maintain the heterochromatin
state (Rountree et al., 2000). With the contribution of Uhrf1
[ubiquitin-like with plant homeodomain (PHD) and ring finger
domains 1], Dnmt1 methylates hemi-methylated DNA generated
upon DNA replication by a mechanism encompassing base
flipping (Song et al., 2011, 2012).
In most mouse cells, Dnmt1 localizes to the cell nucleus.
In fact, Dnmt1 contains several functional nuclear localization
sequences within its N-terminal regulatory domain (Cardoso and
Leonhardt, 1999). In early embryos (Cardoso and Leonhardt,
1999) and in post-mitotic neurons (Inano et al., 2000) though, it
is retained in the cytoplasm. Although highly expressed in mouse
embryos, the exclusion of Dnmt1 from nuclei might inhibit DNA
methylation conservation after DNA replication (Grohmann
et al., 2005), implying that localization of Dnmt1 also regulates
its methylation activity. Within the cell nucleus, the distribution
of Dnmt1 is cell cycle dependent (Leonhardt et al., 1992). In
G1-phase, it is diffusely distributed throughout the nucleoplasm.
In early S-phase, its proliferating cell nuclear antigen (PCNA)-
binding domain (PBD) targets Dnmt1 to replication sites and
in late S-phase, the targeting sequence (TS) further enhances
Dnmt1 binding to replicating pericentromeric heterochromatin
(Schermelleh et al., 2007; Schneider et al., 2013). In G2-phase,
Dnmt1 is de novo loaded onto pericentromeric heterochromatin
via a replication independent mechanism (Easwaran et al., 2004).
Besides its PBD and TS domains, the polybromo-1 protein
homologous domain (PBHD) is also involved in targeting Dnmt1
to replication foci (Liu et al., 1998). Between the TS and PBHD
domains, a CXXC domain can be found in Dnmt1. The CXXC
domain of Dnmt1 occludes access of Dnmt1 catalytic site to
non-methylated CpGs and allows Dnmt1 to bind and specifically
methylate hemi-methylated CpGs (Song et al., 2011).
DNA Base Modifications
The stable covalent C–C bond formed between the methyl group
and the cytosine is difficult to be directly removed and, therefore,
5mC is thought to be a long-lived epigenetic mark. After DNA
replication, Dnmt1 association with the replication machinery
ensures the maintenance of the methylation pattern onto the
newly synthesized strand. Failure to do so, e.g., by retention
in the cytoplasm as mentioned above, leads to gradual passive
loss of DNA methylation over cell generations. DNA replication
independent (active) loss of global DNA methylation was also
observed in some biological processes such as reprogramming
of the paternal genome after fertilization (Mayer et al., 2000)
and development of primordial germ cells (PGC; Hajkova
et al., 2002). The active loss of DNA methylation allows
rapid reprogramming of the genome in a short time. Similar
observations were made in post-mitotic neurons indicating that
active loss of DNA methylation also occurs in somatic cells and
might have important roles in the regulation of gene expression
(Martinowich et al., 2003).
For several decades, scientists have been interested in
identifying pathways or proteins involved in the active loss
of DNA methylation. Lacking the evidence to show that
C–C bonds can be directly broken in mammals, multi-
step processes have been proposed to be involved in the
active removal of DNA methylation marks. In 1972, several
additional modifications of cytosines were described in rat,
mouse, and frog brain tissue including 5-hydroxymethylcytosine
(5hmC), 5-formylcytosine (5fC), 5-carboxylcytosine (5caC), and
5-hydroxymethyluracil (5hmU; Penn et al., 1972; Figure 2).
However, these modifications were considered to be oxidative
damage products of DNA (de Rojas-Walker et al., 1995; Tardy-
Planechaud et al., 1997). Three decades later, 5hmC was re-
discovered in mouse brain tissue (Kriaucionis and Heintz,
2009) and embryonic stem cells (ESCs; Tahiliani et al., 2009).
Furthermore, a family of proteins (ten-eleven translocation, TET)
was identified that oxidize 5mC to 5hmC both in humans
(Tahiliani et al., 2009) and mice (Ito et al., 2010). TET1 was
first described in 2003 as a fusion partner of the mixed lineage
leukemia (MLL) gene in acute myeloid leukemia (AML; Lorsbach
et al., 2003) and 6 years later it was re-discovered as an oxygenase,
which can convert 5mC to 5hmC (Tahiliani et al., 2009). Further
studies showed that Tet proteins also convert 5hmC to 5fC and
5caC (Ito et al., 2011; Pfaffeneder et al., 2011).
Deaminases such as Aid and Apobec can recognize 5mC and
5hmC and further convert 5mC to thymine (T) and 5hmC to
5hmU. Although the deaminase activity is quite low, it is still
a possible pathway for DNA demethylation (Guo et al., 2011).
In addition, Tets were also shown to oxidize T to 5hmU in
mESCs (Pfaffeneder et al., 2014), which additionally leads to loss
of DNA methylation. The oxidation products like 5fC, 5caC,
and 5hmU can be recognized and excised by the glycosylases
Tdg (Maiti and Drohat, 2011) and Neil (Muller et al., 2014)
to create an abasic site on DNA, which is further repaired by
enzymes of the base excision repair (BER) pathway. In addition
to Tdg, 5hmU can also be recognized by other glycosylases like
Mbd4 (Hashimoto et al., 2012b) and Smug1 (Kemmerich et al.,
2012). Accordingly, a combination of oxidation, deamination
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FIGURE 2 | DNA base modifications with respective enzymes. Dnmts catalyze the addition of a methyl group to cytosine bases. Tet proteins oxidize
methylated cytosines to 5hmC, 5fC, and 5caC in an iterative manner. 5mC and 5hmC can be further deaminated by Aid/Apobec to T and 5hmU. T, 5hmU, 5fC, and
5caC can be removed by the indicated glycosylases. Initial references are indicated.
and BER might contribute to the active removal of DNA
methylation. In mouse zygotes, the decrease of 5mC and increase
of 5hmC suggests that 5hmC might be an intermediate of
DNA methylation removal. However, recent studies showed that
loss of 5mC mainly happens before S-phase, whereas gain of
5hmC occurred after DNA replication (Amouroux et al., 2016),
indicating that besides the conversion of 5mC to 5hmC, other
pathways might contribute to methylation removal before DNA
replication in mouse zygotes.
Methylcytosine Modifiers
Until now three members of the Tet protein family named Tet1
(mouse homolog of human TET1), Tet2 (mouse homolog of
human TET2), and Tet3 (mouse homolog of human TET3) have
been identified in mice and humans. All three Tets share a
conserved C-terminal catalytic domain including a cysteine-rich
and a double-stranded β-helix (DSBH) domain, which belong
to the cupin-like dioxygenase superfamily; and exhibit iterative
iron- and oxoglutarate-dependent oxidation activity (Figure 3).
Tissue and Genome-Wide Distribution of Tet
During mouse embryo development, Tet3 is highly expressed in
oocytes and zygotes. Female mice depleted of Tet3 in the germ
line showed severely reduced fecundity and their heterozygous
mutant offspring lacking maternal Tet3 suffer an increased
incidence of developmental failure. Since Tet1, Tet2 as well as
Tet1 and Tet2 double knockout mice are viable, this suggests that
Tet1 and Tet2 are not essential for mouse development (Table 2).
Tet-mediated 5mC to 5hmC conversion is though involved
in reprogramming the paternal genome (Gu et al., 2011; Iqbal
et al., 2011; Wossidlo et al., 2011; Zhang et al., 2012) and also
in reprogramming donor cell DNA during somatic cell nuclear
transfer (Gu et al., 2011). In addition, HIV-1 Vpr binding protein
(VprBP)-mediated monoubiquitylation promotes Tet binding
to chromatin and enhances 5hmC formation (Nakagawa et al.,
2015) in mouse embryos. This process is involved in female germ
cell development and genome reprogramming in zygotes (Yu
et al., 2013).
During PGC reprogramming, Tet1 and Tet2 are highly
expressed (Hackett et al., 2013). However, genome-wide DNA
methylation removal is unaffected by the absence of Tet1 and
Tet2 and, thus, 5hmC, indicating that the first comprehensive
5mC loss does not involve 5hmC formation. Instead Tet1 and
Tet2 have a locus specific role in shaping the PGC epigenome
during subsequent development (Vincent et al., 2013). Further
studies showed that Tet1 has a critical role in the erasure of
genomic imprinting (Yamaguchi et al., 2013) and it controls
meiosis by regulating meiotic gene expression (Yamaguchi et al.,
2012).
In mESCs, both Tet1 and Tet2, as well as their oxidation
product 5hmC are highly abundant (Ito et al., 2010). While Tet2
preferentially acts on gene bodies, Tet1 preferentially acts on
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FIGURE 3 | Schematic representation of the Tet protein family. Shown are domain structures of mouse Tet proteins and the initial references. Numbers
represent amino acid positions. CXXC, CXXC zinc finger domain; Cys, cysteine-rich domain; DSBH, double-stranded β-helix.
TABLE 2 | Phenotypes of initial Tet knockout mouse models.
Genotype Phenotype Reference
Tet1 null Mice are viable, fertile, and grossly normal though some mutant mice have a slightly smaller body size at birth Dawlaty et al., 2011
Tet1 null Animals exhibited abnormal hippocampal long-term depression and impaired memory extinction Rudenko et al., 2013;
Zhang et al., 2013
Tet2 null Approximately one-third of Tet2−/− and 8% of Tet2+/− mice died within 1 year of age because of the development of
myeloid malignancies resembling characteristics of chronic myelomonocytic leukemia, myeloproliferative disorder-like
leukemia, and myelodysplastic syndrome
Li et al., 2011
Tet3 null Female mice depleted of Tet3 in the germ line show severely reduced fecundity and their heterozygous mutant offspring
lacking maternal Tet3 suffer an increased incidence of developmental failure. Oocytes lacking Tet3 also seem to have a
reduced ability to reprogram the injected nuclei from somatic cells
Gu et al., 2011
Tet1 and Tet2 null Double deficient mice had reduced 5hmC and increase 5mC levels and abnormal methylation at various imprinted loci.
Animals of both sexes were fertile with females having smaller ovaries and reduced fertility
Dawlaty et al., 2014
promoters and transcription start sites (TSS; Huang et al., 2014).
Tet1 and Tet2 double knockout ESCs remained pluripotent,
but were depleted of 5hmC and caused developmental defects
in chimeric embryos (Dawlaty et al., 2014). During somatic
reprogramming, Tet2 is required for 5hmC formation at the
Nanog locus (Doege et al., 2012). Further studies showed that
the recruitment of Tet1 by Nanog facilitates the expression of a
subset of reprogramming target genes, such as Oct4 (Costa et al.,
2013). Accordingly, Tet1 can replace Oct4 during somatic cell
reprogramming in conjunction with Sox2, Klf4, and c-Myc (Gao
et al., 2013). The data above indicate that Tet-mediated 5hmC
formation is not only important for ESCs differentiation but also
for somatic reprogramming.
In mouse brain, 5hmC is a constituent of nuclear DNA
(Kriaucionis and Heintz, 2009). Tet1 plays an important
role in regulating neural progenitor cell (NPC) proliferation
in adult mouse brain (Zhang et al., 2013) and is critical
for neuronal activity-regulated gene expression and memory
extinction (Table 2; Rudenko et al., 2013).
Regulation of Tet Activity
Similar to Dnmt1, Tet proteins use a base flipping mechanism to
oxidize 5mC, which includes binding of DNA by a Watson–Crick
polar hydrogen and van der Waals interactions, flipping out 5mC
(Hu et al., 2013; Hashimoto et al., 2014) and oxidation of 5mC
to 5hmC (Hashimoto et al., 2015; Hu et al., 2015). Although Tet
proteins successively oxidize 5mC to 5caC, recent experimental
data showed that, in comparison with 5hmC and 5fC, 5mC is the
preferential substrate for Tet2 (Hu et al., 2015). This preference
was further confirmed by computer simulations (Lu et al., 2016).
In cultured cells, the majority of genomic 5hmC nucleotides
are stable (Bachman et al., 2014), indicating that 5hmC is not
only involved in loss of DNA methylation, but represents an
additional stable epigenetic mark. The global content of 5hmC
varies in mouse tissues, does not correlate with 5mC content
and rapidly decreases as the cells adapt to cell culture conditions
(Nestor et al., 2012). The cell-, tissue-, and developmental stage-
specific distribution of 5hmC indicates that the conversion of
5mC to 5hmC is highly regulated.
Although the N-terminal domain (NTD) of Tet proteins was
shown to be dispensable for their catalytic activity, it was shown
to possess regulatory functions. A CXXC domain, which usually
binds specifically to unmethylated CpGs can be found in the
N-terminus of Tet1 and Tet3 (Liu et al., 2013). While the CXXC
domain of Tet1 cannot bind to DNA in vitro (Frauer et al., 2011b),
it binds to unmodified C, 5mC- or 5hmC-modified CpGs in vivo
(Zhang et al., 2010; Xu Y. et al., 2011). Moreover, binding of the
CXXC domain to DNA was shown to control DNA methylation
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levels by preventing unwanted DNA methyltransferase activity
in ESCs (Xu Y. et al., 2011) or aberrant methylation spreading
into CpG islands (CGIs) in differentiated cells (Jin et al., 2014).
The CXXC domain of Xenopus Tet3 recognizes non-methylated
cytosines in either CpG or non-CpG context, and it is critical for
specific Tet3 targeting (Xu et al., 2012). Although Tet2 proteins
do not have a CXXC domain, recent studies showed that the
ancestral CXXC domain of Tet2 is encoded by a distinct gene
named Idax. Unlike the CXXC domain of Tet1 and Tet3, the
CXXC domain of Idax binds unmethylated CpGs. Through direct
protein–protein interactions of Tet2 and Idax, Tet2 is recruited to
DNA. Furthermore, Tet2 is degraded by caspase activation, which
is triggered by the CXXC of Idax (Ko et al., 2013).
Two parts of the DSBH domain are connected by a potential
regulatory spacer region. Although the spacer region was shown
to be dispensable for 5mC catalytic activity (Hu et al., 2013), post-
translational modifications (PTMs), such as phosphorylation
and O-GlcNAcylation were observed in the spacer region
(Bauer et al., 2015) indicating that it might exhibit regulatory
functions. O-GlcNAc transferase (Ogt) directly interacts with Tet
proteins and consequently Tet proteins are GlcNAcylated. The
GlcNAcylation does not affect the hydroxylation activity of Tet2
and Tet3, rather Tet2 and Tet3 were shown to promote Ogt
activity (Deplus et al., 2013) by enhancing the localization of Ogt
to chromatin (Chen et al., 2013; Ito et al., 2014). However, it was
shown that Ogt drives Tet3 out of the nucleus further affecting its
activity on DNA (Zhang et al., 2014). In mESCs, Ogt is recruited
to unmethylated CpG promoters in a Tet1-dependent manner
(Vella et al., 2013). In addition to PTMs, mutations within the
spacer region of Tet2 were observed in myelodysplastic syndrome
(MDS), thus further highlighting the importance of this region
(Ko et al., 2010).
In vivo, besides PTMs, Tet activity is regulated by protein–
protein interactions, such as with Sin3a. In mESCs, the
interaction between Sin3a and Tet1 allows Sin3a to repress a
subset of Tet1 target genes (Williams et al., 2011). In mouse
zygotes, Tet3-mediated 5mC to 5hmC conversion is involved in
reprogramming of the paternal but not the maternal genome
although they share the same cytoplasm (Mayer et al., 2000). The
resistance of the maternal genome to reprogramming is achieved
by a protein named developmental pluripotency associated 3
(Dppa3, or PGC7). Dppa3 binds to histone H3K9me2 (Nakamura
et al., 2012) and interacts with Tet3 further blocking the activity of
Tet3 (Bian and Yu, 2014). Dazl, an RNA-binding protein known
to play a key role in germ cell development, was shown to enhance
Tet1-mediated 5mC to 5hmC conversion by enhancing Tet1
protein translation (Welling et al., 2015). In addition, growth
arrest and DNA damage inducible protein 45 (Gadd45) interacts
with Tet1 and Tdg and promotes loss of DNA methylation by
enhancing 5fC/5caC removal (Kienhöfer et al., 2015; Li et al.,
2015).
Finally, Tet-mediated 5mC to 5hmC conversion was shown
to be regulated by Tet cofactors. 2-Ketoglutarate (2-KG), one
of the cofactors for Tet oxidation is produced by isocitrate
dehydrogenase 1/2 (Idh1/2) in vivo. However, mutated Idh1/2
produce 2-hydroxyglutarate, a competitive inhibitor of 2-KG,
which can further inhibit 5mC to 5hmC conversion (Konstandin
et al., 2011). Vitamin C is a potential cofactor for Tet-mediated
oxidation and was shown to enhance Tet activity, which leads
to increased global 5hmC in ESCs (Blaschke et al., 2013). ATP
was also shown to be involved in regulating Tet activity. In vitro,
the reaction of Tet-mediated 5mC to 5caC can be enhanced by
addition of ATP (He et al., 2011).
Hydroxymethylcytosine maintenance
Dnmt1 recognizes hemi-mC DNA and methylates the nascent
DNA strand after replication during the S-phase of the cell
cycle. However, in vitro studies showed a 60-fold decreased
binding ability of Dnmt1 to hemi-hmC DNA compared to hemi-
mC DNA (Hashimoto et al., 2012a), indicating that hemi-hmC
DNA might not be a substrate for Dnmt1. Previous studies
showed that Np95 can recognize 5hmC and bind to hemi-
hmC DNA (Frauer et al., 2011a), indicating that Np95 might
target Dnmt1 to hemi-hmC containing replication forks to
maintain hmC after DNA replication. In addition, Dnmt3a and
Dnmt3b recognize hemi-hmC DNA (Hashimoto et al., 2012a)
and are necessary for methylation maintenance at repeat genomic
elements (Chen et al., 2003) suggesting Dnmt3a/3b might play
a role in maintaining 5hmC after DNA replication in repeat
elements.
In vivo, the majority of 5hmC is present in CpG dinucleotides.
However, 5hmC has also been observed in non-CpG context,
especially in gene bodies (Pastor et al., 2011; Xu Y. et al.,
2011). One important role of CpG methylation in gene
promoter regions is the repression of gene expression by directly
or indirectly preventing interactions between promoter and
transcription factors. Hydroxymethylated CpGs might affect
binding of transcription factors and/or 5mC readers to DNA.
DNA MODIFICATION READERS
In mammals, the methylome is specifically read by a variety of
proteins known as methyl-CpG binding proteins (MBPs), which
based on structural features are further classified into three main
families: the methyl-CpG binding domain (MBD) protein family
(Lewis et al., 1992; Cross et al., 1997; Hendrich and Bird, 1998;
Hendrich and Tweedie, 2003; Laget et al., 2010; Baymaz et al.,
2014), the Kaiso protein family (Daniel and Reynolds, 1999;
Filion et al., 2006), and the SET and RING (really interesting new
gene) finger associated (SRA) domain protein family (Hopfner
et al., 2000; Mori et al., 2002). While initially identified as 5mC
binding proteins, recent studies indicate that a distinct and
dynamic set of MBPs binds the Tet oxidation product 5hmC
during differentiation (Figure 4; Frauer et al., 2011a; Mellen et al.,
2012; Spruijt et al., 2013). Through further interactions with
multiple protein partners, MBPs provide a link between cytosine
derivatives and functional chromatin states in a temporally and
spatially regulated fashion.
MBD Protein Family
Presently, the MBD protein family consists of eleven members
(Mecp2, Mbd1–6, SETDB1, SETDB2, TIP5/BAZ2A, and BAZ2B;
Lewis et al., 1992; Cross et al., 1997; Hendrich and Bird, 1998;
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FIGURE 4 | 5-(Hydroxy)methylcytosine readers. Shown are MBPs that
read 5mC and 5hmC as indicated and the initial references.
Hendrich and Tweedie, 2003; Laget et al., 2010; Baymaz et al.,
2014). All of them share a common protein motif, the 70–
85 amino acids long MBD, which enables some, but not all
family members, to selectively bind to single methylated CpG
dinucleotides. With the exception of Mbd2 and Mbd3, MBD
proteins bear little resemblance outside their MBD (Hendrich
and Bird, 1998). Instead, MBD proteins comprise several
distinct domains that confer unique DNA binding, as well
as other functional features. Since this review covers DNA
(hydroxy)methylation-dependent processes, we will thereafter
focus on MBD family members (Figure 5) capable of binding
to (hydroxy)methylated CpG dinucleotides, i.e., methyl-CpG
binding protein 2 (Mecp2) and methyl-CpG binding domain
proteins 1–4 (Mbd1–4).
Mecp2
The first protein described to selectively recognize and bind
single, symmetrically methylated CpG dinucleotides was Mecp2
(Lewis et al., 1992). It is abundantly expressed in the central
nervous system with the highest protein levels in post-mitotic
neurons (Akbarian et al., 2001; Traynor et al., 2002; Jung et al.,
2003). Of the two alternatively spliced isoforms (Mecp2 e1
and e2), which differ in their N-terminus, Mecp2 e2 was first
identified and is, therefore, best characterized (Kriaucionis and
Bird, 2004; Mnatzakanian et al., 2004). Although both isoforms
distribute differently in developing and post-natal mouse brains,
no functional differences have been identified so far (Dragich
et al., 2007).
Both Mecp2 variants include two functionally characterized
domains, the MBD and the transcriptional repression domain
(TRD). While the MBD proved sufficient to direct specific
binding to methylated cytosines (Nan et al., 1993), the TRD was
originally identified as the region required for transcriptional
repression in vitro and in vivo (Lewis et al., 1992; Nan et al.,
1997; Jones et al., 1998; Kaludov and Wolffe, 2000). Circular
dichroism and protease digestion analysis revealed that outside
these functional domains the full-length protein is largely devoid
of secondary structure (Adams et al., 2007). With almost 60%
unstructured regions, Mecp2 is reckoned among the intrinsically
disordered proteins, which often undergo a disorder-to-order
transition upon binding to other macromolecules (Adams et al.,
2007). Indeed, recent studies demonstrate that Mecp2 gains
secondary structure and acquires substantial thermal stabilization
upon binding to DNA (Ghosh et al., 2010). Unlike its name
implies DNA binding is, however, not solely mediated via its
5mC specific MBD. Instead, as indicated by the release of Mecp2
upon salt extraction, regions outside the MBD contribute to
the overall binding energy through electrostatic interactions
(Meehan et al., 1992). As shown by electrophoretic mobility
shift assays (EMSAs), these sequence-unspecific DNA binding
motifs include the TRD and, based on their relative location
to the MBD and TRD, the so-called intervening domain, as
well as the C-terminal domain alpha (Ghosh et al., 2010). The
NTD of Mecp2 in contrast, contributes indirectly to the overall
binding affinity by enhancing the methylation specificity of the
MBD through conformational coupling (Ghosh et al., 2010).
An analog synergistic increase in DNA binding efficiency was
observed through interdomain interactions between the TRD
and the C-terminal part of the protein (Ghosh et al., 2010).
Similar to the NTD, the C-terminal domain beta (CTD beta)
does not directly interact with DNA (Ghosh et al., 2010).
Nevertheless, the overall chromatin binding efficiency was lost
upon its deletion (Nikitina et al., 2007b). Consistent with this,
the CTD beta induced moderate and reproducible shifts with
nucleosomal arrays, but not with naked DNA (Ghosh et al.,
2010), suggesting that the most C-terminal 192 residues of Mecp2
harbor a chromatin interaction surface (Nikitina et al., 2007b).
Indeed, Mecp2 has been shown to interact with histone H3 and,
similar to the linker histone H1, binds to nucleosomes close
to the linker DNA entry–exit site (Nikitina et al., 2007b). As a
result, the entering and exiting linker DNA segments are brought
in close proximity to form a stem-like motif (Nikitina et al.,
2007a), which bears strong resemblance to structures induced
by H1 (Hamiche et al., 1996; Bednar et al., 1998). The modes
of chromatin compaction, however, differ significantly from each
other. While histone H1 arranges nucleosomes and linker DNA
into regular zigzag-shaped chromatin fibers (Woodcock, 2006),
Mecp2 forms highly compacted globular structures in vitro due
to its multiple DNA and chromatin binding domains (Georgel
et al., 2003). Accordingly, Mecp2 was shown to induce clustering
of pericentric heterochromatin in a dose-dependent manner
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FIGURE 5 | Schematic representation of the MBD protein family. Shown are domain structures of mouse MBD proteins and the initial references. Numbers
represent amino acid positions. MBD, methyl-CpG binding domain; CXXC, CXXC zinc finger domain; TRD, transcriptional repression domain; GR, glycine/arginine;
E, glutamic acid.
in vivo to establish a locally repressive chromatin environment
(Brero et al., 2005; Agarwal et al., 2011). More recently, Szulwach
et al. (2011) provided evidence that binding of Mecp2 to
methylated CpG dinucleotides may protect 5mC against Tet-
mediated oxidation thereby preventing reactivation of silenced
genes. The underlying mechanism, however, has so far not been
described.
An additional level of regulation is achieved through various
protein–protein interactions. While direct homo- and hetero-
interactions of Mecp2 and Mbd2 were shown to cross-link
chromatin fibers (Becker et al., 2013), physical associations of
Mecp2 with the transcriptional co-repressor Sin3a and histone
deacetylase 2 (HDAC2) via its TRD contribute to the global
heterochromatin architecture through histone hypoacetylation
(Jones et al., 1998; Nan et al., 1998). Consequently, Mecp2
deficiency was demonstrated to result in global changes in
neuronal chromatin architecture, elevated histone acetylation
levels, and increased transcriptional noise in a DNA methylation-
dependent manner (Skene et al., 2010; Cohen et al., 2011).
A number of other repressive protein partners of Mecp2
have been identified including the co-repressors c-Ski (Kokura
et al., 2001), CoREST (Lunyak et al., 2002), and NCoR/SMRT
(Stancheva et al., 2003), as well as DNA methyltransferase Dnmt1
(Kimura and Shiota, 2003) and H3K9 methyltransferase (Fuks
et al., 2003).
Both, binding of Mecp2 to DNA, as well as interactions
with protein partners are affected by PTMs. Neuronal activity
induced phosphorylation and dephosphorylation of Mecp2 was
shown to modulate its association with promoters of specific
genes, as well as with interaction partners (reviewed in Li and
Chang, 2014). More recently, poly(ADP-ribosyl)ation of Mecp2
in mouse brain tissue was reported, which anticorrelated with
its chromatin binding affinity and clustering ability (Becker
et al., 2016). Furthermore, ubiquitylation (Gonzales et al., 2012),
SUMOylation (Cheng et al., 2014), acetylation (Zocchi and
Sassone-Corsi, 2012), and methylation (Jung et al., 2008) were
shown to substantially contribute to the functional versatility of
Mecp2.
Another unanticipated level of functional complexity was
demonstrated by recent work of Spruijt et al. (2013) who
identified Mecp2 as reader of 5hmC in mESC by quantitative
mass-spectrometry-based proteomics. Moreover, independent
studies of Mellen et al. (2012), revealed Mecp2 as the major
5hmC-binding protein in mouse brain, which moreover turned
out to bind both, 5hmC- and 5mC-containing substrates with
similar affinity.
Finally, chip-chip analysis using antibodies against MECP2
in a human neuronal cell line demonstrated that around two-
third of strongly MECP2 bound promoters were transcriptionally
active (Yasui et al., 2007). Subsequent analysis of gene expression
patterns in Mecp2 knockout and overexpressing mice concurred
that Mecp2 functions as an activator as well as a repressor of
transcription (Chahrour et al., 2008).
Hence, the traditional view of Mecp2 as a 5mC-dependent
transcriptional silencer may be incomplete and its biology
appears far more complicated than previously assumed.
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Both, male and female mice lacking Mecp2 (Table 3)
developed an uncoordinated gait and reduced spontaneous
movement between 3 and 8 weeks of age and most died
between 6 and 12 weeks (Chen et al., 2001; Guy et al.,
2001). Furthermore, most animals developed hind limb clasping,
irregular breathing, misaligned jaws and uneven wearing of
teeth. Mutant brains were reduced in weight, however, no
structural abnormalities or signs of neurodegeneration were
detected, suggesting that stability of brain function, not brain
development per se, is impaired in the absence of Mecp2.
Consistent with this hypothesis, re-expression of the Mecp2
gene in Mecp2lox−Stop/y mice proved sufficient to reverse the
neurological symptoms of Rett syndrome (RTT), indicating
that Mecp2-deficient neurons develop normally and are not
irreversibly damaged (Guy et al., 2007). Further microarray
analyses revealed that knockout of Mecp2 implicates only minor
changes in gene expression (Tudor et al., 2002). Subsequent
studies demonstrating increased expression restricted to non-
coding RNA in brain of Mecp2-deficient mice (Muotri et al.,
2010; Skene et al., 2010), indicated that Mecp2 may not
act as a gene-specific transcriptional repressor, but might
instead dampen transcriptional noise genome-wide in a DNA
methylation-dependent manner (Skene et al., 2010). Accordingly,
expression of repetitive elements (Muotri et al., 2010; Skene et al.,
2010) as well as retrotransposition of LINE1 was increased in
brain of Mecp2-deficient mice (Muotri et al., 2010).
Mbd1
Mbd1, initially termed PCM1, is expressed in somatic cells
and represents the largest member of the MBD family (Cross
et al., 1997; Hendrich and Bird, 1998). Similar to Mecp2, Mbd1
contains a MBD and a TRD, which have analog functions to that
of Mecp2 (Ng et al., 2000). In addition, depending on the isoform,
Mbd1 contains two or three CXXC zinc finger motifs (Fujita
et al., 1999; Jorgensen et al., 2004). The most C-terminal one,
referred to as CXXC3, is homolog to zinc fingers found in Dnmt1,
CpG binding protein CGBP, histone H3K4 methyltransferase
MLL and histone H3K36 deacetylases of the Jumonji family
JHDM1A and JHDM1B (Jorgensen et al., 2004; Lee and Skalnik,
2005; Tsukada et al., 2006). While CXXC3 was shown to bind
unmethylated CpG dinucleotides in vitro (Birke et al., 2002; Lee
and Skalnik, 2002, 2005; Jorgensen et al., 2004), the remaining
zinc finger motifs of Mbd1 lack a conserved glutamine residue
and the characteristic KFFG motif necessary for binding to DNA
(Jorgensen et al., 2004). Accordingly, Mbd1 isoforms containing
the first two CXXC domains preferentially bind methylated DNA
via their MBD, whereas isoforms comprising a complete set
of zinc fingers have the ability to bind both, methylated and
unmethylated substrates (Jorgensen et al., 2004; Baubec et al.,
2013).
As a transcriptional repressor, Mbd1 was thus shown to
inhibit transcription from both, methylated and unmethylated
promoters in reporter gene assays (Fujita et al., 1999; Jorgensen
et al., 2004). While methylation-dependent silencing is mediated
by the MBD and TRD, suppression of non-methylated reporter
constructs required the presence of the CXXC3 domain
(Jorgensen et al., 2004). Although, a precise association between
Mbd1 and HDACs has not been described, transcriptional
repression was partially sensitive to trichostatin A (TSA), an
HDAC inhibitor (Ng et al., 2000). In most assays, however, Mbd1
behaved as an HDAC-independent repressor (Ng et al., 2000).
Instead, MBD1 has been found associated with histone H3K9
methyltransferases SETDB1 (Sarraf and Stancheva, 2004) and
Suv39h1 (Fujita et al., 2003). Association to SETDB1 mediates
transcriptional repression throughout the cell cycle (Sarraf and
Stancheva, 2004). During S-phase, however, MBD1 was shown
to recruit SETDB1 to the large subunit of chromatin assembly
factor CAF-1 to form an S-phase specific complex that mediates
methylation of H3K9 in a post-replicative manner (Sarraf and
Stancheva, 2004). Accordingly, H3K9 methylation is lost in the
absence of MBD1 and results in activation of specific genes, such
as p53BP2 (Sarraf and Stancheva, 2004).
MBD1-mediated transcriptional repression and hetero-
chromatin maintenance was shown to be regulated by
SUMOylation (Lyst et al., 2006; Uchimura et al., 2006). In human
cells, two E3 SUMO-ligases (PIAS1 and PIAS3) were shown to
SUMOylate MBD1 (Lyst et al., 2006). While SUMO1-conjugation
blocks the MBD1 and SETDB1 interaction, modification with
SUMO2/3 recruits SETDB1 thereby stimulating its repressive
function (Uchimura et al., 2006).
Although mice lacking Mbd1 (Table 3) developed normally
and appeared healthy throughout life, they were impaired
in spatial learning, had decreased neurogenesis and reduced
long-term potentiation in the dentate gyrus of the hippocampus
TABLE 3 | Phenotype of initial MBP-deficient mouse models.
Genotype Phenotype Reference
Mecp2 null Rett syndrome-like phenotype. Between 3 and 5 weeks: uncoordinated gait, reduced spontaneous movement, hind
limb clasping, irregular breathing, misaligned jaws, uneven wearing of teeth, reduced brain weight, and neuronal cell
size. Between 6 and 12 weeks: rapid weight loss and death.
Chen et al., 2001;
Guy et al., 2001
Mbd1 null Viable and fertile. Impaired spatial learning, decreased neurogenesis, reduced long-term potentiation, decreased
genomic stability.
Zhao et al., 2003
Mbd2 null Viable, fertile. Maternal nurturing defects: reduced litter size and weight of pups. Hendrich et al., 2001
Mbd3 null Early embryonic lethality Hendrich et al., 2001
Mbd4 null Viable and fertile. Increased number of C:G to T:A transitions at CpG sites. Millar et al., 2002
Kaiso null Viable and fertile. Reduced tumorigenesis Prokhortchouk et al., 2006
Np95 null Early gestational lethality. Developmental arrest shortly after gastrulation. Sharif et al., 2007
Np97 null Phenotype not described. Li et al., 2013
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(Zhao et al., 2003). Moreover, Mbd1-deficient neural stem cells
differentiated less and had decreased genomic stability (Zhao
et al., 2003).
Mbd2
Mbd2 and Mbd3 are the only known members of the MBD
protein family with significant sequence similarity beyond the
MBD (Hendrich and Bird, 1998) and, thus, are believed to
have arisen from an ancient duplication during evolution of
the vertebrate lineage (Hendrich and Tweedie, 2003). Consistent
with this, a homolog Mbd2/3 like protein was identified in
invertebrates, including Drosophila (Lyko et al., 2000; Marhold
et al., 2004). Despite the high degree of sequence similarity,
Mbd3 lacks the amino-terminal extension of Mbd2, which
contains a repeat consisting of glycine and arginine residues
(Hendrich and Bird, 1998). While both, Mbd2 and Mbd3 contain
a C-terminal coiled coil (CC) domain that mediates protein–
protein interactions, Mbd3 was shown to comprise an additional
glutamic acid repeat at its extreme COOH-terminus (Hendrich
and Bird, 1998; Gnanapragasam et al., 2011; Becker et al., 2013).
Mbd2 contains two in-frame start codons, which give rise to
Mbd2a and the truncated version Mbd2b, which lacks the first
140 amino acids (Hendrich and Bird, 1998). In vivo, however,
only Mbd2a, but not Mbd2b, has been detected (Ng et al., 1999).
Inclusion of an alternative third exon gives rise to an additional
isoform of Mbd2, named Mbd2c, which lacks the C-terminal
TRD and CC domain due to an early stop codon (Hendrich and
Bird, 1998).
Tethering of Mbd2a near a promoter via a GAL4 DNA
binding domain was shown to mediate transcriptional repression
that is sensitive to TSA (Ng et al., 1999). Similarly, Mbd2b
enhanced transcriptional repression of methylated reporter
constructs in co-transfection assays (Boeke et al., 2000). Different
from other MBD family members, the sequence required for TRD
partially overlapped with the MBD (Boeke et al., 2000), indicating
a strong interrelation of methylation binding and transcriptional
silencing. In line with this, the TRD directly interacts with the
transcriptional repressor Sin3A (Boeke et al., 2000). Moreover,
Mbd2 co-purified with a large protein complex known as NuRD
(nucleosome remodeling and histone deacetylation), which
includes chromatin remodeling ATPase Mi-2, as well as HDAC1
and HDAC2 (Ng et al., 1999; Wade et al., 1999; Zhang et al., 1999;
Mahajan et al., 2005; Le Guezennec et al., 2006). EMSAs indicated
that Mbd2a directs the NuRD complex, which is implicated
in transcriptional silencing, to methylated DNA (Zhang et al.,
1999). Finally, immunoprecipitation analysis showed that Mbd2
associates with HDAC1 in mammalian cells and is the long
sought methyl-CpG binding component of the 400–800 kDa
MeCP1 complex (Meehan et al., 1989; Ng et al., 1999).
Mbd2 was shown to bind 5mC in a manner similar to the
isolated MBD of Mecp2 (Hendrich and Bird, 1998; Wade et al.,
1999). Binding of oxidative 5mC derivatives, however, has not
been observed (Hashimoto et al., 2012a; Mellen et al., 2012;
Spruijt et al., 2013).
Mbd2b has also been reported to have DNA demethylase
activity (Bhattacharya et al., 1999), but this finding has been
questioned (Ng et al., 1999; Wade et al., 1999).
Mbd2-deficient mice (Table 3) are viable and fertile, but
exhibit a maternal nurturing defect resulting in reduced litter size
and weight of pups (Hendrich et al., 2001).
Mbd3
The smallest member of the MBD family, coding for a protein
of approximately 30 kDa is Mbd3 (Hendrich and Bird, 1998). It
appears in a rich diversity of splice variants and is expressed in
ESCs as well as somatic tissues (Hendrich and Bird, 1998; Roloff
et al., 2003).
DNA binding properties of Mbd3 seem to vary with
species. While mammalian Mbd3 is unable to interact with
methylated DNA, its amphibian counterpart binds methylated
CpG dinucleotides in vitro and in vivo (Hendrich and Bird,
1998; Wade et al., 1999; Saito and Ishikawa, 2002). Sequence
comparison of 5mC binding competent MBD domains revealed
two highly conserved residues, which are altered in mammalian
Mbd3: a largely solvent exposed tyrosine, as well as an amino-
terminal lysine or arginine residue (Ohki et al., 1999; Wakefield
et al., 1999; Saito and Ishikawa, 2002).
Despite its inability to recognize 5mC, three different Mbd3
isoforms (Mbd3a–c) that vary in their amino termini were
detected within the NuRD repression complex in embryonic stem
cells (Zhang et al., 1999; Kaji et al., 2006). ESCs lacking Mbd3-
NuRD displayed a severe defect in differentiation that lead to
persistent self-renewal even in the absence of leukemia inhibitory
factor (Kaji et al., 2006). More recently, depletion of Mbd3 in
somatic cells was shown to enhance the reprogramming efficiency
of the four Yamanaka factors (Oct4, Sox2, Klf4, and Myc; Luo
et al., 2013; Rais et al., 2013). Accordingly, Mbd3 was proposed
to play a key role in lineage commitment and pluripotency
(Yildirim et al., 2011; Reynolds et al., 2012; Whyte et al., 2012).
Contradictory studies using neural and epiblast-derived stem
cells, however, indicate a role for Mbd3 in facilitating induction of
pluripotency and argue that its function may be context specific
(dos Santos et al., 2014).
Binding sites of Mbd3 have been mapped genome-wide in
mouse and human cells (Yildirim et al., 2011; Baubec et al.,
2013; Gunther et al., 2013; Shimbo et al., 2013). While Yildirim
et al. (2011) identified Mbd3 bound to TSS of CpG-rich,
hydroxymethylation marked promoters, Baubec et al. (2013)
found Mbd3 bound to enhancers independent of CpG density
and (hydroxy)methylation status. Further data questioning the
interaction of Mbd3 with hydroxymethylated DNA was provided
by Spruijt et al. (2013), who did not detect Mbd3 among
hydroxymethylation-specific readers.
Although both, Mbd2 and Mbd3 associate with the NuRD
complex, the two MBD containing complexes appear to have
no functional overlap since knockout of Mbd3 in mice is
embryonic lethal, whereas Mbd2-deficient mice are viable and
fertile (Hendrich et al., 2001; Table 3).
Mbd4
Mbd4, also referred to as MED1 (Bellacosa et al., 1999), is the
only known member of the MBD protein family not associated
with HDAC activity (Hendrich and Bird, 1998). Instead, several
lines of evidence suggest that Mbd4 plays a role in DNA repair
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(Bader et al., 1999; Bellacosa et al., 1999; Hendrich et al.,
1999; Riccio et al., 1999; Petronzelli et al., 2000; Millar et al.,
2002). In addition to its MBD, Mbd4 contains a C-terminal
catalytic domain that is highly homologous to bacterial DNA
damage specific endonucleases that exhibit glycosylase activity
during BER (Michaels et al., 1990; Hendrich and Bird, 1998).
Accordingly, Mbd4 was shown to remove thymine or uracil
from mismatched CpG sites through glycosidic bond cleavage.
As genomic G/T mismatches are the expected product of 5mCpG
deamination, Mbd4 has been designated a methylation specific
DNA repair enzyme (Hendrich et al., 1999; Petronzelli et al.,
2000; Hashimoto et al., 2012b). Furthermore, Mbd4 has been
implicated in DNA demethylation as it was shown in vitro to
excise 5hmU, the deamination product of 5hmC (Hashimoto
et al., 2012b).
Knockout and rescue experiments in embryonic stem cells,
however, demonstrated that oxidation-dependent reactivation of
methylated reporter genes is mediated by the action of thymine
DNA glycosylase (TDG), but not by Mbd4 (Muller et al., 2014).
Accordingly, deamination of 5hmC to 5hmU and subsequent
excision by Mbd4 does not play a major role in ESCs (Hashimoto
et al., 2012b). A contribution of Mbd4 to Tet-initiated DNA
demethylation in NPCs, however, cannot be excluded, since
Mbd4 was shown to bind to 5hmC at this developmental stage
(Spruijt et al., 2013).
Mice lacking Mbd4 are viable and fertile (Millar et al., 2002).
However, compared to wild-type mice, Mbd4 knockout lead to
a 3.3-fold higher number of C:G to T:A transitions at CpG sites
(Millar et al., 2002). Moreover, Mbd4−/− mice that were made
heterozygous for the Min allele of the adenomatous polyposis coli
gene (ApcMin), which pre-disposes mice to develop spontaneous
intestinal neoplasia (Su et al., 1992), showed markedly reduced
survival compared to Mbd4+/+ controls. Accordingly, Mbd4
plays an important role in the repair of 5mC deamination
at mCpGs. The relatively mild phenotype of Mbd4 knockout
mice (Table 3), however, suggests that its absence might be
compensated for by other glycosylases, such as TDG.
Kaiso Protein Family
Members of the Kaiso-like protein family (Figure 6) present
a second class of proteins capable of binding specifically
to methylated DNA (Filion et al., 2006). In contrast to
members of the MBD protein family, Kaiso, Zbtb4, and Zbtb38
contain a conserved BTB/POZ (Bric-a-brac, tramtrack, broad
complex/poxvirus and zinc finger) domain involved in protein–
protein interactions and three Kruppel-like C2H2 zinc finger
motifs, of which two were found essential for binding to
methylated DNA (Filion et al., 2006). Similar to MBD proteins,
members of the Kaiso family function as HDAC-dependent
transcriptional repressors (Sasai et al., 2005). Several lines of
evidence, however, including their variable binding modes,
protein partners and expression patterns, suggest that Kaiso-like
proteins have different biological functions (Daniel and Reynolds,
1999; Kiefer et al., 2005; Park et al., 2005; Filion et al., 2006).
While Kaiso was shown to require at least two methylated
CpG dinucleotides, a single mCpG proved sufficient for efficient
binding of the Zbtb4 and Zbtb38 proteins (Prokhortchouk et al.,
2001; Filion et al., 2006). Besides its ability to bind methylated
DNA, in vitro synthesized Kaiso was shown to interact specifically
with an unmethylated consensus sequence, the Kaiso binding
site (KBS, TCCTGCNA), which can be found at promoters of
Wnt target genes (Daniel and Reynolds, 1999; Park et al., 2005).
Accordingly, the xWnt11 gene, a target of non-canonical Wnt
signaling, was shown to be regulated by Kaiso in Xenopus (Daniel
and Reynolds, 1999; Prokhortchouk et al., 2001). Moreover,
Kaiso-mediated repression of non-canonical and canonical Wnt
targets was repressed by interactions with p120-catenin (Kim
et al., 2004), as it competes with DNA for the access to the
Kaiso zinc finger domains (Daniel et al., 2002). The ability to
bind unmethylated KBS sequences is shared by Zbtb4. Zbtb38,
however, was shown to interact with the E-box motif (CACCTG)
of the rat tyrosine hydroxylase gene promoter (Kiefer et al., 2005),
but failed to bind a labeled KBS probe (Filion et al., 2006). More
recently, Kaiso was found to bind 5hmC in NPCs and Zbtb4
was pulled down with hydroxymethylated DNA from brain tissue
(Spruijt et al., 2013). The 5hmC binding domains, as well as the
biological function, however, remain to be determined.
Kaiso-like proteins contain a BTB/POZ domain, which
facilitates interaction with different sets of co-repressors and
mediate transcriptional repression.
Kaiso was shown to recruit the NCoR complex to promoters
of target genes to introduce histone hypoacetylation, as well
as H3K9 methylation (Yoon et al., 2003). Moreover, Kaiso
was identified as component of an alternative MeCP1 complex
in NIH3T3 cells (Prokhortchouk et al., 2001). Zbtb38 was
found to interact with the co-repressors CtBPs (C-terminal
binding proteins), which include HDAC, methyltransferase,
and demethylase activities (Sasai et al., 2005; Zocchi and
Sassone-Corsi, 2012). Zbtb4 was shown to associate with the
Sin3A/HDAC complex to repress expression of p21CIP1 in
response to stimuli that activate p53 (Weber et al., 2008).
Kaiso-like proteins exhibit diverging expression patterns.
While Kaiso is ubiquitously expressed, Zenon, the rat homolog
of ZBTB38, is primarily transcribed in brain and neuroendocrine
tissues (Kiefer et al., 2005). For Zbtb4, in contrast, high expression
levels were identified in brain, lung, kidney, muscle, and heart
(Filion et al., 2006).
Kaiso-null mice (Table 3) are viable and fertile, with no
detectable changes in gene expression profiles or developmental
abnormalities. However, when crossed with tumor-susceptible
Apc(Min/+) mice, Kaiso-deficient animals showed resistance to
intestinal cancer (Prokhortchouk et al., 2006).
SRA Domain Protein Family
Recent studies implicate that yet another protein fold, the SRA
domain could read DNA (hydroxy)methylation marks in vitro
and in vivo (Unoki et al., 2004; Johnson et al., 2007; Woo
et al., 2007; Frauer et al., 2011a; Spruijt et al., 2013). In
mammals, two SRA domain-containing proteins (Figure 7),
Np95 (mouse homolog of human ICBP90, gene name UHRF1)
and Np97 (mouse homolog of human NIRF, gene name UHRF2),
have been characterized (Unoki et al., 2004; Woo et al.,
2007; Zhang et al., 2011). While Np95 was first discovered
during the generation process of antibodies against murine
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FIGURE 6 | Schematic representation of the Kaiso-like protein family. Shown are domain structures of mouse Kaiso-like proteins and the initial references.
Numbers represent amino acid positions. BTB/POZ, broad complex, tramtrack and bric a brac/poxvirus and zinc finger domain; ZF, zinc finger; CXXC, CXXC zinc
finger domain.
FIGURE 7 | Schematic representation of the SRA domain protein family. Shown are domain structures of mouse SRA domain proteins and the initial
references. Numbers represent amino acid positions. UBL, ubiquitin-like domain; TTD, tandem tudor domain; PHD, plant homeodomain; SRA, SET, and RING finger
associated domain; RING, really interesting new gene.
thymic lymphoma (Fujimori et al., 1998), NIRF was identified
through screenings for PCNP (PEST containing nuclear protein)
interaction partners (Mori et al., 2002).
Besides the eponymous SRA domain, ICBP90 contains at
least four additional functional motifs (Hashimoto et al., 2009):
an N-terminal ubiquitin-like domain (Ubl, or NIRF_N); a
tandem Tudor domain (TTD) that binds histone H3 tails di/tri-
methylated at lysine 9 (H3K9me2/3; Karagianni et al., 2008;
Papait et al., 2008; Rottach et al., 2010); a PHD, which binds
(un)modified histones; and a C-terminal RING, which exhibits
ubiquitin E3 ligase activity.
ICBP90 and Np95 play a critical role in epigenetic inheritance
and maintenance of DNA methylation (Bostick et al., 2007; Sharif
et al., 2007). Accordingly, ICBP90/Np95 was shown to colocalize
with PCNA during S phase and to interact with Dnmt3a, Dnmt3b
and several histone-modifying enzymes like HDAC1, as well as
histone methyltransferase G9a (Achour et al., 2009; Kim et al.,
2009; Meilinger et al., 2009). Moreover, besides its ability to
bind and flip out hemi-methylated DNA, the SRA domain of
ICBP90 was shown to target Dnmt1 to replicating pericentric
heterochromatin for maintenance methylation (Bostick et al.,
2007; Arita et al., 2008; Avvakumov et al., 2008; Hashimoto
et al., 2008; Papait et al., 2008). In addition, ICBP90 was
shown to bind histone H3K9me2/3 via its TTD, thus connecting
repressive histone marks with DNA methylation (Rottach et al.,
2010; Nady et al., 2011; Rothbart et al., 2012). The PHD of
ICBP90, on the other hand, was found associated with the
N-terminal tail of histone H3 (Papait et al., 2007; Hu et al., 2011;
Rajakumara et al., 2011; Wang et al., 2011; Arita et al., 2012;
Cheng et al., 2013). More recently, the SRA domain of Np95
was demonstrated to bind 5hmC and 5mC containing DNA
substrates with similar affinity in vitro (Frauer et al., 2011a).
Consistent with this, Np95 was identified as 5hmC reader in
mESCs and NPCs. In mouse brain tissue, however, association
with 5hmC remained undetected likely due to its low expression
levels. Although the structure of NIRF, the second member of
the SRA domain protein family, is closely related to ICBP90,
both proteins possess significantly different expression patterns.
While ICBP90 is mainly expressed in proliferating cells (Fujimori
et al., 1998), NIRF protein levels increase during differentiation
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(Pichler et al., 2011). NIRF binds hemi-methylated DNA and
H3K9me2/3 containing heterochromatin marks in a cooperative
manner, whereby localization and in vivo binding dynamics of
NIRF, were shown to require an intact TTD and depend on
H3K9me3 but not on DNA methylation (Pichler et al., 2011).
While Np95 was shown to bind 5hmC in mESCs and NPCs,
the interaction of Np97 and 5hmC was specific for NPCs.
Furthermore, Np97 exhibited higher binding affinity for 5hmC
than for 5mC in NPCs (Spruijt et al., 2013). Finally, Np97 was
proposed to promote repetitive oxidation of 5mC by Tet proteins,
since the levels of the oxidative cytosine derivatives 5hmC, 5fC
and 5caC were increased upon coexpression of Np97 and Tet1
in HEK293T cells (Spruijt et al., 2013). Consequently, Spruijt
et al. (2013), hypothesized that flipping of the modified base,
as previously described for Np95, may enhance the accessibility
of Tet enzymes to the hydroxymethylated base, whereby further
oxidation is promoted.
Furthermore, ectopic Np97 was unable to rescue DNA
methylation defects observed in Np95−/− ESCs. Neither DNA
methylation levels, nor pericentric heterochromatin localization
of Dnmt1 in S-phase could be restored upon overexpression of
Np97 arguing for functional differences between both proteins
(Pichler et al., 2011). NIRF was found to interact with cell cycle
proteins including cyclins, cyclin-dependent kinases (CDKs),
retinoblastoma protein (pRB), p53, PCNA, HDAC1, DNMTs, and
G9a (Mori et al., 2012). It was shown to ubiquitinate cyclins D1
and E1, and to induce G1 arrest. Accordingly, NIRF was proposed
to link the cell cycle regulatory network with the epigenetic
landscape (Mori et al., 2012).
While knockout of Np95 leads to developmental arrest shortly
after gastrulation and early gestational lethality (Sharif et al.,
2007), the phenotype of Np97 null mice has not been analyzed
(Li et al., 2013; Table 3).
ROLE OF 5mC WRITERS, READERS,
AND MODIFIERS IN DISEASE
Mutations in proteins involved in writing, reading, and
modifying the epigenetic landscape have been implicated in
various severe human disorders. Due to their high sequence
(Table 4) and functional similarity (Kumar et al., 1994; Hendrich
and Bird, 1998; Mori et al., 2002; Filion et al., 2006; Bostick et al.,
2007; Ito et al., 2010; Qin et al., 2011), we, hereafter, summarize
the state-of-the-art regarding the role of the human orthologs
of the aforementioned mouse Dnmts, Tets, and MBPs in human
diseases.
DNMT Proteins in Disease
Since Dnmt1 knockout is embryonic lethal in mice, it is
unlikely to expect a human disease linked to a DNMT1
catalytic domain mutation. But mutations in the regulatory
domain of DNMT1 were found (Table 5). Mutations in
the TS domain of DNMT1 cause neurodegeneration like
hereditary sensory autonomic neuropathy with dementia and
hearing loss (HSAN1E; Klein et al., 2011) and autosomal
TABLE 4 | Comparison of human proteins and their mouse orthologs.
Mouse protein Human protein Amino acid similarity (%)
Dnmt1 (1620 aa) DNMT1 (1632 aa) 76
Dnmt2 (415 aa) DNMT2 (391 aa) 77
Dnmt3a (908 aa) DNMT3A (912 aa) 96
Dnmt3b (860 aa) DNMT3B (853 aa) 80
Dnmt3l (421 aa) DNMT3L (387 aa) 56
Tet1 (2039 aa) TET1 (2136 aa) 50
Tet2 (1912 aa) TET2 (2002 aa) 55
Tet3 (1803 aa) TET3 (1795 aa) 89
Mecp2 (501 aa) MECP2 (498 aa) 94
Mbd1 (636 aa) MBD1 (605 aa) 68
Mbd2 (414 aa) MBD2 (411 aa) 94
Mbd3 (285 aa) MBD3 (291 aa) 92
Mbd4 (554 aa) MBD4 (580 aa) 58
Kaiso (671 aa) KAISO (672 aa) 84
Zbtb4 (982 aa) ZBTB4 (1013 aa) 85
Zbtb38 (1197 aa) ZBTB38 (1195 aa) 81
Np95 (782 aa) ICBP90 (806 aa) 72
Np97 (803 aa) NIRF (802 aa) 90
dominant cerebellar ataxia, deafness and narcolepsy (ADCA-
DN; Winkelmann et al., 2012). Mutations of Y495C, Y495H,
D490E-P491Y (Klein et al., 2011, 2013) in exon 20 cause
HSAN1E. Those mutations caused premature degradation
of mutant proteins, reduced methyltransferase activity and
impaired heterochromatin binding during G2 phase leading
to global hypomethylation and site-specific hypermethylation
(Klein et al., 2011). ADCA-DN is a polymorphic disorder first
described in 1995 in a Swedish pedigree. Unlike mutations in
HSAN1E located in exon 20, mutations in ADCA-DN including
A570V, G605A, and V606F were found in exon 21 of the DNMT1
gene.
Mutations in DNMT3A were found in de novo AML
and are associated with poor survival (Table 5; Ley et al.,
2011). The most frequent mutation occurred in amino acid
R882, however, frameshift, nonsense and splice site mutations
were also reported (Ley et al., 2011). Mutations of DNMT3A
are not only observed in AML patients, but also in MDS.
Similar to mutations leading to AML, amino acid R882 located
in the methyltransferase domain of DNMT3A is the most
common mutation site (Walter et al., 2011). Unlike in AML
and MDS, most mutations in overgrowth syndrome do not
directly affect the catalytic activity of DNMT3A, but interfere
with domain–domain interactions and histone binding, which
further affect the activity of DNMT3A (Tatton-Brown et al.,
2014).
ICF syndrome (immunodeficiency, chromosomal instability,
and facial anomalies), a human genetic disorder is caused by
DNMT3B mutations (Table 5; Hansen et al., 1999; Xu et al.,
1999). Several mutations were identified and most mutations
are located in the catalytic domain of DNMT3B and directly
affect the activity of DNMT3B (Xu et al., 1999). However,
mutations, which do not directly affect its catalytic activity were
also observed in ICF syndrome. Two mutations, A766P and
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TABLE 5 | Summary of disease-related DNMT and TET mutations.
Protein Disease Alteration Reference
DNMT1 Hereditary sensory autonomic neuropathy with dementia
and hearing loss (HSAN1E)
Y495C, Y495H, D490E-P491Y Klein et al., 2011, 2013
DNMT1 Autosomal dominant cerebellar ataxia, deafness and
narcolepsy (ADCA-DN)
A570V, G605A, and V606F Winkelmann et al., 2012
DNMT3A Acute myeloid leukemia (AML) myelodysplastic syndrome
(MDS)
R882 and frameshift, nonsense and splice site mutations Ley et al., 2011;
Walter et al., 2011
DNMT3A Overgrowth syndrome Mutations interfere with domain–domain interactions and
histone binding
Tatton-Brown et al., 2014
DNMT3B Immunodeficiency, centromeric region instability, facial
anomalies syndrome (ICF) syndrome
Mutations in catalytic domain Hansen et al., 1999;
Xu et al., 1999
TET1 AML Ten-eleven translocation that gives rise to a MLL-TET1
fusion
Lorsbach et al., 2003
TET2 AML, MDS, and myeloproliferative neoplasms Mutations mostly in catalytic domain Abdel-Wahab et al., 2009
R840Q displayed similar methylation activity than the wild-type
enzyme but lost the ability to interact with DNMT3L, which
further leads to loss of activity in vivo (Xie et al., 2006). Direct
or indirect loss of DNMT3B activity consequently decreased
satellite DNA methylation in ICF syndrome patients, indicating
that DNMT3B is involved in maintaining genome stability.
5mC, the product of DNMTs is related to tumorigenesis.
It was shown that the genome of cancer cells is globally
hypomethylated relative to their normal counterparts. Usually,
hypomethylation leads to gene activation. In cancer cells, the
activation of genes is caused by hypomethylation of nearby
CGIs, which are silenced in somatic tissues by DNA methylation
(Strichman-almashanu et al., 2002). Satellite sequences and
repetitive sequences such as LINE1, SINE, IAP, and Alu elements
are silenced mainly by DNA methylation in normal cells.
However, in tumor cells, hypomethylation of L1 promoter was
detected and the activation of L1 might promote chromosomal
rearrangements and genome instability (Suter et al., 2004).
Although the cancer genome is hypomethylated, several studies
showed that Dnmts are upregulated in cancer cells (Ahluwalia
et al., 2001; Lin et al., 2007; Roll et al., 2008), suggesting that
demethylation enzymes might be additionally involved in loss of
DNA methylation in cancer.
TET Proteins in Disease
MLL gene is located in 11q23 and is the most frequent cytogenetic
finding in AML. In AML, MLL is translocated to chromosome
10 as a fusion with the TET1 gene. The MLL-TET1 fusion
protein contains the AT hooks, subnuclear localization domains,
and the CXXC domain of MLL and the C-terminus of TET1
(Table 5; Lorsbach et al., 2003). The function of MLL-TET1
fusion protein is still unknown, but it was showed that TET1 is
involved in MLL-rearranged leukemia. TET1 is a direct target of
the MLL-fusion protein and is significantly upregulated in MLL-
rearranged leukemia, leading to a global increase 5hmC, thus
playing an oncogenic role (Huang et al., 2013).
In myeloproliferative neoplasms, mutations of TET2 but not
TET1 and TET3 were observed (Table 5; Abdel-Wahab et al.,
2009). Mutations of TET2 were also observed in AML with varied
frequency and most of them occurred in the catalytic domain of
TET2. In AML, TET2 mutations correlate with genomic 5hmC
level (Konstandin et al., 2011). TET2 is one of the most frequently
mutated genes in MDS. Mutations of TET2 were detected in
most of the bone marrow cells in MDS and these mutations
contribute to the malignant transformation of bone marrow
cells (Langemeijer et al., 2009), which consequently displayed
uniformly low levels of 5hmC in genomic DNA compared to
bone marrow samples from healthy controls (Ko et al., 2010).
Besides the hematopoietic malignancies, 5hmC levels are also
changed in solid tumors. 5hmC level were profoundly reduced in
glioma, colon cancer, breast cancer, and melanoma compared to
normal tissues (Haffner et al., 2011; Jin et al., 2011; Li and Liu,
2011; Xu W. et al., 2011; Kraus et al., 2012).
Unlike in cancer, in the hippocampus/parahippocampal gyrus
(HPG) of preclinical and later-stage Alzheimer’s disease patients,
significantly increased levels of TET1, 5mC, and 5hmC were
observed. In contrast, levels of 5fC and 5caC were significantly
decreased in the HPG of these patients (Bradley-Whitman and
Lovell, 2013). This indicates that DNA methylation might play an
important role in memory-related disease.
MBPs in Disease
As readers and translators of epigenetic information, alterations
in MBP sequences affect the precisely coordinated link between
DNA methylation, histone modification and higher order
chromatin structure.
Mutations in the X-linked MECP2 gene give rise to RTT
(Table 6), a late onset (6–18 months post-birth) debilitating
neurological disease that affects 1 in 10,000–15,000 female live
births (Hagberg et al., 1983; Amir et al., 1999). After a period of
normal development (6–18 months), RTT patients usually lose
speech and acquired motor skills (Hagberg et al., 1983). They
are aﬄicted with seizures, autism, loss of motor coordination,
abnormal breathing and develop stereotypical, repetitive hand
movements (Hagberg et al., 1983). After the initial regression,
however, conditions often stabilize and allow viability until
adulthood (Rett, 1966; Hagberg et al., 1983).
Although the first patients were described in 1966 by Andreas
Rett (Rett, 1966), more than 30 years passed before mutations
within the MECP2 gene located in Xq28 were identified as
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TABLE 6 | Summary of disease-related MBP alterations.
Protein Disease Alteration Reference
MECP2 Rett syndrome Causal MECP2 mutations of Rett syndrome are
summarized in: http://mecp2.chw.edu.au/mecp2/index.php
Amir et al., 1999
MBD1 Prostate cancer Upregulated Patra et al., 2003
MBD2 Breast cancer Upregulated Billard et al., 2002







Riccio et al., 1999
KAISO Colorectal cancer Upregulated Lopes et al., 2008
ZBTB4 Neuroblastoma Downregulated Weber et al., 2008
ICBP90 Non-small-cell lung cancer Upregulated Daskalos et al., 2011
NIRF Lung cancer Upregulated He et al., 2009
the cause of the neurological disorder (Amir et al., 1999). The
most frequent mutations observed in patients suffering from
RTT are missense mutations that cluster within the MBD (aa
78–162), as well as nonsense mutations primarily found within
the TRD (aa 207–310; Christodoulou et al., 2003). In Xenopus,
missense mutations R106W, R133C, F155S, and T158M were
shown to reduce the binding ability of Mecp2 to methylated
DNA (Ballestar et al., 2000). Studies in mouse cells showed
that the majority of MBD-related missense mutations affected
the heterochromatin binding and/or clustering ability of Mecp2
(Agarwal et al., 2011). By artificially targeting chromatin binding
deficient Rett mutants (R111G, R133L, and F155S) to constitutive
heterochromatic regions, however, Casas-Delucchi et al. (2012)
revealed that some of these mutations exclusively affect the
chromatin binding but not linking ability. Mutations within the
TRD have been shown to influence protein–protein interactions.
In knock-in mice bearing the common RTT mutation R306C,
neuronal activity fails to induce T308 phosphorylation, a PTM
required to suppress the interaction of Mecp2 with the co-
repressor complex NCoR. Accordingly, R306C mutations result
in persistent association of both proteins leading to decreased
induction of a subset of activity-related genes (Ebert et al.,
2013; Lyst et al., 2013). In addition to missense and nonsense
mutations, reading frame shifts and C-term deletions were shown
to give rise to RTT. Mice bearing a truncating mutation similar
to those found in RTT patients showed normally localized
Mecp2 proteins (Shahbazian et al., 2002). Histone H3, however,
was hyperacetylated indicating abnormal chromatin architecture
and misregulated gene expression (Shahbazian et al., 2002).
Moreover, Muotri et al. (2010) identified increased susceptibility
for L1 transposition and genome instability in RTT patients with
truncating mutations.
In addition to RTT, Mecp2 was implicated in other
neurological diseases, including Hirschsprung’s disease, autism
spectrum disorder, schizophrenia, Prader-Willi, and Angelman
syndromes (Carney et al., 2003; Shibayama et al., 2004; Nagarajan
et al., 2006; Loat et al., 2008; Ramocki et al., 2009; Zhou et al.,
2013).
More recently MBP have been associated with several types
of human cancers (Table 6). While Mecp2 was overexpressed in
estrogen receptor positive human breast cancer (Muller et al.,
2003), MBD1 mRNA and protein levels were increased in
FIGURE 8 | Writing, reading, and translating DNA modifications. Graphical summary of how DNA modification writers, readers, and translators can impact on
chromatin composition, structure (nucleosomes are represented as balls, DNA as line) as well as genome expression (arrow represents active promoters) and
stability.
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prostate cancer (Patra et al., 2003). Accordingly, Patra et al.
(2003) proposed MBD1 as the major cause of hypermethylated
chromatin regions in prostate cancer through the recruitment of
HDAC1/2 and subsequent histone deacetylation. MBD2 mRNA
level were shown to be significantly elevated in benign tumors
of the breast and correlated with tumor size of invasive ductal
carcinomas, the most common type of breast cancer (Billard
et al., 2002). Accordingly, upregulation of MBD2 was proposed
to be associated with breast cell proliferation (Billard et al., 2002).
Increased expression of MBD3 and MBD4 were associated with
malignant glioma of the brain, and the grade of malignancy
correlated with MBD3/4 expression level (Schlegel et al.,
2002). Furthermore, frameshift mutations of MBD4 have been
identified in colorectal, endometrial and pancreatic cancer with
microsatellite instability (Riccio et al., 1999). MBD4 mutations
consisted of 1- to 2-bp deletions or 1-bp insertions that caused
frameshifts and premature stop codons. The resultant truncated
MBD4 proteins were predicted to be non-functional, as they lack
the C-terminal catalytic domain, whereby genomic instability was
proposed to steadily increase (Riccio et al., 1999). As a regulator
of target genes of the canonical and non-canonical Wnt pathway,
Kaiso was shown to mediate silencing of tumor suppressor genes
CDKN2A and HIC1 in Wnt-driven human colon cancer cell
lines (Lopes et al., 2008). Kaiso depletion induced expression
of tumor suppressor genes without altering DNA methylation
levels (Lopes et al., 2008). As a result, colon cancer cells
became susceptible to cell cycle arrest and cell death induced
by chemotherapy (Lopes et al., 2008). Accordingly, Lopes et al.
(2008) suggested Kaiso as a methylation-dependent oncogene
that represses hypermethylated tumor suppressor genes. ZBTB4
expression was shown to be downregulated in advanced stages of
human neuroblastoma and multiple human solid tumors (Weber
et al., 2008). As a repressor of the P21CIP1 gene, an inhibitor of the
Cdk2 kinase, ZBTB4 usually blocks cell cycle arrest in response to
p53 activation (Weber et al., 2008). Consequently, loss of ZBTB4
inhibits apoptosis and favors long-term survival of affected cells
(Weber et al., 2008). In tumors, where many promoter-associated
CGIs are hypermethylated, maintenance of methylation plays a
major role. Accordingly, elevated levels of ICBP90 were shown to
control cell cycle through maintenance of promoter methylation
at CDK2A and RASSF1 in non-small-cell lung cancer (Daskalos
et al., 2011). Finally, decreased expression of let-7a miRNA in
lung cancer was shown to result in elevated NIRF and reduced
P21CIP1 protein level, thereby most likely contributing to lung
carcinogenesis (He et al., 2009).
CONCLUDING REMARKS
In summary, alterations in 5mC writers, readers, and modifiers
that affect their level, PTMs, ability to bind and/or modify DNA
and protein interactions are each and all potential mechanisms
contributing to altered chromatin composition and structure as
well as genome activity and stability (Figure 8) and contribute
to an overwhelming variety of human diseases. Despite intensive
research, genotype–phenotype connections have been generally
difficult to establish and subsequent studies are urgently needed
to elucidate potential strategies for diagnostic and therapeutic
applications.
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